Latest news
Relay Therapeutics: Buy Rating Reaffirmed with Unchanged $29 Price Target on Multiple Upcoming Clinical and Regulatory Catalysts - TipRanksTipRanks · Fri, 07 Aug 2026 21:23:12 GMTBoris Peaker Reiterates Buy on Relay Therapeutics, Citing Advancing Zovegalisib Phase III Program, Rich 2026–2027 Catalyst Calendar, and Solid Cash Position Supporting Favorable Risk‑Reward - TipRanksTipRanks · Fri, 07 Aug 2026 13:45:51 GMTRelay Therapeutics price target raised to $30 from $27 at Barclays - TipRanksTipRanks · Fri, 07 Aug 2026 09:48:14 GMTAnalyst Reiterates Buy on Relay Therapeutics, Citing Lead Asset Zovegalisib’s Phase 3 Upside and Strong Cash Runway into 2029 - TipRanksTipRanks · Fri, 07 Aug 2026 09:43:38 GMTTD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating - MoomooMoomoo · Fri, 07 Aug 2026 09:26:23 GMTRelay Therapeutics Expands ATM Equity Offering Agreement - TipRanksTipRanks · Thu, 06 Aug 2026 21:11:52 GMTGoldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX) - The Globe and MailThe Globe and Mail · Tue, 28 Jul 2026 11:46:00 GMT